Dr Victoria S Pao, MD | |
19842 Lake Chabot Rd, Castro Valley, CA 94546-4002 | |
(510) 537-1577 | |
(510) 537-1436 |
Full Name | Dr Victoria S Pao |
---|---|
Gender | Female |
Speciality | Plastic And Reconstructive Surgery |
Experience | 26 Years |
Location | 19842 Lake Chabot Rd, Castro Valley, California |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295726768 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | A70717 (California) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Eden Medical Center | Castro valley, CA | Hospital |
Mailing Address | Practice Location Address |
---|---|
Dr Victoria S Pao, MD 20055 Lake Chabot Rd, Suite 340, Castro Valley, CA 94546-5331 Ph: (510) 537-1577 | Dr Victoria S Pao, MD 19842 Lake Chabot Rd, Castro Valley, CA 94546-4002 Ph: (510) 537-1577 |
News Archive
Surgeons who engage in minimally invasive, laparoscopic surgery are providing great benefits to their patients, but possibly to their own detriment. That's the finding of the largest survey ever conducted of surgeons in North America who perform laparoscopic procedures.
Sorin Group,, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that it received the CE Mark approval for the Mitroflow Aortic Pericardial Heart Valve with PRT.
African-American women with breast cancer were more likely to have larger, later-stage tumors that were more difficult to treat and also had lower survival rates than Hispanic and Caucasian women who received the same treatment in two independent series of clinical trials examined by researchers from The University of Texas M. D. Anderson Cancer Center.
Perrigo Company plc announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex 600mg Extended-Release tablets.
Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients.
› Verified 7 days ago